Rocilinostat is a specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. HDAC inhibitors focus on HDAC enzymes, hindering the growth of cancer cells and triggering apoptosis, the programmed death of cancer cells. Reagent grade, for research purpose.